Enveric BiosciencesNASDAQ: ENVB

IND filing and first-in-human Phase 1 clinical trial initiation targeted 2026

Why it matters: With FDA recommending direct IND submission and all preclinical/CMC milestones complete, EB-003 is positioned for IND filing in 2026. Cash position ($4.7M at Dec 2025 + ~$3M raised early 2026) may require additional fundraising to fully fund Phase 1.

Watch next: IND filing date; Phase 1 FIH design and site selection; potential partnership or financing announcement

Actual: Jan 1, 2024

EB-003 elevated to lead development candidate from the EVM301 tryptamine series

Why it matters: EB-003 is a non-hallucinogenic tryptamine derivative designed to selectively engage both 5-HT2A and 5-HT1B receptors — the first known compound designed for this dual-receptor profile. Promotes neuroplasticity at DMT-equivalent levels without hallucinogenic effects, enabling potential home use.

Actual: Jan 1, 2025

USPTO Notice of Allowance for EB-003 patent (composition of matter + methods of use)

Why it matters: Composition of matter patent provides the strongest possible IP protection for EB-003. Additional EVM301 series patent also allowed (December 2025), building a multi-patent IP fortress.

Actual: Aug 1, 2025

Pre-IND 7-day Dose Range Finding (DRF) toxicology studies completed in two species; Maximum Tolerated Dose (MTD) established

Why it matters: Two-species tox studies with established MTD are a key IND requirement. Completion signals EB-003 is ready for IND filing.

Actual: Sep 1, 2025

FDA pre-IND response received — FDA recommended proceeding directly to IND submission (skip pre-IND meeting)

Why it matters: FDA telling a sponsor to skip the pre-IND meeting and go straight to IND is a positive signal — it means the agency views the preclinical package as sufficiently complete to support human dosing without further discussion.

Actual: Sep 2, 2025

Corporate HQ relocated to Cambridge, MA

Why it matters: Cambridge/Boston biotech cluster provides proximity to KOLs, talent, and potential pharma partners.

Actual: Sep 15, 2025

Positive preclinical PTSD data: EB-003 decreased context-induced freezing behavior in validated PTSD animal model

Why it matters: First preclinical evidence that EB-003's non-hallucinogenic neuroplasticity translates to functional improvement in a PTSD model. Supports the PTSD indication for the IND filing.

Actual: Oct 1, 2025

Key CMC milestones completed: pharmaceutically compatible salt form identified; scalable synthetic route for kg-quantity manufacturing established

Why it matters: Manufacturing readiness (CMC) is often a bottleneck for novel compounds. Scalable synthesis de-risks the IND filing and Phase 1 drug supply.